Systemic Lupus Erythematosus (SLE) Drug Development

Creative Biolabs has the most professional platform in terms of drug research of autoimmune diseases. We aim to help customers around the world solve the problem of drug development for systemic lupus erythematosus (SLE).

Introduction to Systemic Lupus Erythematosus (SLE)

SLE is one of the commonest autoimmune diseases affecting young and middle-aged females. The patient's lymphocytes go out of control and attack the body's tissues. It can involve almost every organ. Much information about the genetic background of the pathogenesis and environmental risk factors for SLE has been revealed in recent years, and this can partly explain the diverse nature of the disease. Although survival of SLE patients has improved in recent years, a small part of patients still develops progressive therapy-refractory disease.

Pathophysiology of SLE. Fig.1 Pathophysiology of SLE. (Shreya, 2020)

Treatment of SLE

Patients with SLE usually need a life-long treatment in both light and severe clinical presentation of the disease. In the current condition, immunomodulatory agents, hydroxychloroquine, cyclophosphamide, biologic agents, and glucocorticoids are recommended for the treatment of SLE. While these drugs work for some patients, they do not work for others and can even make the condition worse.

  • B Cells
  • Due to limited treatment options, new and novel therapeutic approaches are necessary. Because B cells have an active role in the pathophysiology of SLE, scientists believe that B cells also show an attractive target for therapies evolving in the autoimmune diseases field. The eradication of B cells, along with the potential for T cell persistence, has resulted in prolonged remission or stable disease. Amongst these, immune effector cell therapies, including chimeric antigen receptor (CAR)-T cell therapy, have proven beneficial in targeting B cells.

  • Autologous hematopoietic stem cell transplantation (AHSCT)
  • Autologous hematopoietic stem cell transplantation (AHSCT) has been proposed as a treatment modality that may arrest the autoimmune disease process and lead to sustained treatment-free remissions. There was general agreement among experts in this field, that in patients with severe SLE refractory to conventional immunosuppressive therapies, AHSCT can achieve sustained clinical remissions (ranging from 50-70% disease-free survival at 5 years).

Our Drug Development Services

Creative Biolabs is the premier provider that strives to provide the highest quality autoimmune disease drug development services. We have five major antigen expression platforms to meet your needs for recombinant expression. The antibodies prepared by our team have the advantages of high specificity and good stability which are widely used in basic research. With many years of antibody development experience, Creative Biolabs provides comprehensive services, including but not limited to:

  • Monoclonal Antibody Development for SLE
  • Bispecific Antibody Development for SLE
  • Cell-based Therapy for SLE

With more than 10 years of research experience, Creative Biolabs provides comprehensive drug development services for our customers worldwide. If you are interested in our services, please contact us.

Reference

  1. Shreya, Patel.; et al. Expanding the Role of CAR-T Cell Therapy to Systemic Lupus Erythematosus. EMJ Hematol. 2020, 8 [1]: 105-112.

For Research Use Only | Not For Clinical Use



Online Inquiry

Autoimmune Diseases

We are dedicated to advancing and facilitating your drug development against autoimmune diseases

Contact us

USA

  • Location:

  • Call:

  • Fax:

  • Email:

UK

  • Location:

  • Call:

  • Email:

Autoimmune Diseases,Drug Development for
Autoimmune Diseases

Creative Biolabs is a world-leading CRO that is skilled in developing novel therapies,
especially in antibody and cell therapy for autoimmune diseases.

Copyright © 2022 Creative Biolabs. All Rights Reserved.